<DOC>
	<DOCNO>NCT02759315</DOCNO>
	<brief_summary>The study single-center , multiple-arm investigation co-administration MK-3682 450 mg Ruzasvir ( MK-8408 ) 60 mg participant chronic Hepatitis C Virus ( HCV ) Genotype ( GT ) 1 , GT2 , GT3 , GT4 , GT5 , GT6 . The impact study treatment regimen Sustained Virologic Response ( SVR ) 12 ( undetectable HCV ribonucleic acid [ RNA ] 12 week end study treatment ) HCV Genotype evaluate cirrhotic participant non-cirrhotic participant .</brief_summary>
	<brief_title>Efficacy Safety MK-3682 With Ruzasvir ( MK-8408 ) Adults With Chronic Hepatitis C Genotype 1 , 2 , 3 , 4 , 5 6 Infection ( MK-3682-035 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Has Hepatitis C Virus ( HCV ) ribonucleic acid ( RNA ) time screen Has document chronic HCV Genotype ( GT ) 1 , GT2 , GT3 , GT4 , GT5 , GT6 evidence nontypeable mixed GT infection Is otherwise healthy determine medical history , physical examination , electrocardiogram ( ECG ) , clinical laboratory measurement perform time screening Has absence cirrhosis compensate cirrhosis Is HCV treatmentnaïve experience virologic failure complete prior interferoncontaining regimen Is nonchildbearing potential agrees avoid become pregnant impregnating partner begin least 2 week prior administration initial dose study drug 14 day last dose study drug For human immunodeficiency virus ( HIV ) coinfected participant : currently antiretroviral therapy ( ART ) plan initiate ART treatment participate study Or wellcontrolled HIV ART Is mentally legally incapacitate , significant emotional problem ( screen expect study ) history clinically significant psychiatric disorder would interfere study procedure . Has evidence decompensated liver disease manifest presence history ascites , esophageal gastric variceal bleeding , hepatic encephalopathy sign symptom advance liver disease Is ChildPugh Class B C PughTurcotte ( CPT ) score &gt; 6 cirrhotic Is coinfected Hepatitis B Virus Has history opportunistic infection precede 6 month prior screen coinfected HIV Has history malignancy ≤5 year prior study start ( except adequately treat basal cell squamous cell skin cancer situ cervical cancer carcinoma situ ) evaluation active suspect malignancy Has cirrhosis liver image within 6 month prior study start show evidence hepatocellular carcinoma ( HCC ) evaluation HCC Is take medication herbal supplement restrict study entry criterion period ≤2 week prior study start 2 week last dose study drug Has clinicallyrelevant drug alcohol abuse within 12 month study start Has participate clinical study investigational product within 30 day prior first dose study drug Is female pregnant breastfeeding , expect conceive donate egg least 2 week prior study start 14 day last dose study drug Is male expect donate sperm least 2 week prior Day 1 14 day last dose study drug Has following : organ transplant ( include hematopoietic stem cell transplant ) cornea hair ; poor venous access ; history gastric surgery ; history malabsorption disorder Has cardiac abnormalities/dysfunction include limited : unstable angina ; unstable congestive heart failure ; unstable arrhythmia Has history medical/surgical condition result hospitalization within 3 month prior study start , minor elective procedure Has medical condition requiring , likely require , chronic systemic administration corticosteroid , tumor necrosis factor ( TNF ) antagonists , immunosuppressant drug study Has evidence history chronic hepatitis cause HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>